Con­side­ring these chal­len­ges, phar­maceuti­cal and me­di­cal tech­no­logy com­pa­nies are ope­ra­ting dy­na­mi­cally in an ex­tre­mely com­pe­ti­tive en­viron­ment cha­rac­te­ri­zed by on­go­ing cost pres­sure, steadily in­cre­asing re­gu­la­tion, and vo­la­tile supply chains. On aver­age, Ger­man phar­maceuti­cal com­pa­nies in­vest more than 10% of their an­nual sa­les in in-house re­se­arch and de­ve­lop­ment - more than any other in­dus­try sec­tor.

Of the nearly 700 Ger­man com­pa­nies fal­ling un­der the phar­maceuti­cal sec­tor, more than 90% are SMEs and Mid­Caps. With sa­les of EUR 49 bil­lion in 2021, the Ger­man phar­maceuti­cal mar­ket ranks fourth world­wide, be­hind the USA, China, and Ja­pan, and has also es­ta­blis­hed its­elf as the lar­gest phar­maceuti­cal mar­ket in Eu­rope. Its im­port­ance lies par­ti­cu­larly in its strong roots in small and me­dium-si­zed en­ter­pri­ses. Wi­thin Ger­many, around half of SHI mar­ket sa­les in 2022 will be ac­coun­ted for by pa­tent-pro­tec­ted drugs, fol­lo­wed by off-pa­tent in­itial supplier pro­ducts with 32% and fi­nally ge­ne­rics / bio­si­mi­lars with 22%. It should be em­pha­si­zed that the share of drugs ap­pro­ved in Ger­many is roughly the same for pre­scrip­tion and over-the-coun­ter drugs.

The me­di­cal tech­no­logy sec­tor in Ger­many is also do­mi­na­ted by me­dium-si­zed com­pa­nies. 93% of the nearly 1,500 med­tech com­pa­nies em­ploy up to 250 peo­ple. In ad­di­tion, Ger­many also plays a lea­ding role here at in­ter­na­tio­nal le­vel. In 2021, the Eu­ro­pean med­tech sec­tor ge­ne­ra­ted va­lue ad­ded of more than 140 bil­lion eu­ros, of which Ger­many holds the lea­ding po­si­tion with a mar­ket share of more than 26%. In com­pa­ri­son, Eu­rope's se­cond lar­gest mar­ket player, France, ac­coun­ted for only 15% of sa­les. The im­pres­sive ex­port ra­tio of 67% in 2022 fur­ther un­ders­cores the in­ter­na­tio­nal com­pe­ti­tiv­en­ess and in­no­va­tive strength of the Ger­man me­di­cal tech­no­logy sec­tor.

As a stra­te­gic part­ner with a clear fo­cus and many years of ex­pe­ri­ence in these in­dus­try seg­ments, we are fa­mi­liar with the com­ple­xity of the in­dus­try and its va­rious sta­ke­hol­ders, un­der­stand the re­gu­latory re­qui­re­ments as well as the in­ter­na­tio­nal cha­rac­ter and are very aware of the high in­no­va­tive strength of the com­pa­nies in these mar­kets. We go beyond pure con­sul­ting and are at your side to fur­ther de­ve­lop your com­pany and busi­ness mo­del, to se­cure sus­tai­nable com­pe­ti­tive ad­van­ta­ges in the fu­ture or to work out suc­ces­sion so­lu­ti­ons. Be­ne­fit from our busi­ness and fi­nan­cial, tax or le­gal ex­per­tise as well as our ex­ten­sive con­sul­ting and tran­sac­tion ex­pe­ri­ence in these in­dus­tries. Our de­di­ca­ted team works hand in hand to de­ve­lop cu­st­omi­zed so­lu­ti­ons for you that are not only con­vin­cing on pa­per but can also be suc­cess­fully im­ple­men­ted in prac­tical day-to-day busi­ness.

You can rely on our in­ter­di­sci­pli­nary coope­ra­tion, in which our au­di­tors, tax con­sul­tants, la­wy­ers and ma­nage­ment con­sul­tants work clo­sely to­ge­ther to en­sure that your con­cerns are in the best hands.